Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
Dávid Dóra, Syeda Mahak Zahra Bokhari, Kenan Aloss, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2769-2769
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Xing Kang, Harry Cheuk-Hay Lau, Jun Yu
Cell Reports Medicine (2024) Vol. 5, Iss. 4, pp. 101478-101478
Open Access | Times Cited: 41
Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis
Xinpei Li, Shijie Shang, Meng Wu, et al.
Cancer Letters (2024) Vol. 598, pp. 217096-217096
Closed Access | Times Cited: 11
Pathogenic mechanisms of immune checkpoint inhibitor (ICI)-associated retinal and choroidal adverse reactions
Rachana Haliyur, Victor M. Elner, Thérèse M. Sassalos, et al.
American Journal of Ophthalmology (2025)
Closed Access | Times Cited: 1
Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis
Qimei Fang, Qian Yan, Zhaolu Xie, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis
Vanessa G. P. Souza, Aisling Forder, Liam J. Brockley, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8894-8894
Open Access | Times Cited: 18
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Xuwen Lin, Mei Xie, Jie Yao, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 5
Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors
Jinglong Huang, Caifeng Gong, Aiping Zhou
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 11
Obesity, dysbiosis and inflammation: interactions that modulate the efficacy of immunotherapy
Ashutosh S. Yende, Dipali Sharma
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota
Alberto Vogrig, Marta Dentoni, Irene Florean, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Characterization of the gut microbiota in drug abuse: prediction, prevention, and personalized medicine to benefit affected populations
Xin Wang, Yajie Yu, Cai Liao, et al.
The EPMA Journal (2025)
Closed Access
Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients
Dávid Dóra, Péter Revisnyei, Alija Pašíć, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential
Mohammad Hossein Nemati, Esmaeil Yazdanpanah, Roya Kazemi, et al.
Biology (2025) Vol. 14, Iss. 4, pp. 435-435
Open Access
Mechanisms by which the intestinal microbiota affects gastrointestinal tumours and therapeutic effects
Jikai He, Haijun Li, Jiaqi Jia, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 10
The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer
Sen Wang, Benling Xu, Yangyang Zhang, et al.
Cancer Biology and Medicine (2023), pp. 1-18
Open Access | Times Cited: 10
Immunotherapy Influence On Human Body: Glycan Engineering Antibody-Based Cancer Treatments
Kafayat Motomori Bakare, Anyanwu Nkeiruka, Ugochukwu Okwudili Matthew, et al.
Journal of Community Medicine and Public Health Reports (2024)
Open Access | Times Cited: 3
From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy
David Dora, Emőke Szőcs, Ádám Soós, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 453-453
Open Access | Times Cited: 2
The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
Huaju Yang, Zheran Liu, Ruidan Li, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Clinical Applications of the Gut Microbiome in Genitourinary Cancers
Charles B. Nguyen, Ulka N. Vaishampayan
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
Juan Chen, Jia-Si Liu, Junyan Liu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e009399-e009399
Open Access | Times Cited: 1
Decoding the microbiota metabolome in hepatobiliary and pancreatic cancers: Pathways to precision diagnostics and targeted therapeutics
Yuemiao Xu, Jiahan Le, Jiang‐Jiang Qin, et al.
Pharmacological Research (2024) Vol. 208, pp. 107364-107364
Open Access | Times Cited: 1
Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD‐L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy
Lijun Yue, Feng Geng, Jiayi Jin, et al.
Biotechnology Journal (2024) Vol. 19, Iss. 12
Closed Access | Times Cited: 1
Novel thiazole/ethyl thiazole carboxylate-acetamide derivatives and their cytotoxic effect evaluation
Asaf Evrim Evren, Sam Dawbaa, Demokrat Nuha, et al.
Kocatepe Veterinary Journal (2024)
Open Access
Metabolic pathways from the gut metatranscriptome are associated with COPD and respiratory function in lung cancer patients
David Dora, Péter Revisnyei, Anna Mihucz, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access
Causal relationship between gut microbiota and lung squamous cell carcinoma: a bidirectional two-sample Mendelian randomization study
Weijian Song, Jianwei Shi, Minjun Du, et al.
Postgraduate Medical Journal (2024)
Closed Access
Page 1 - Next Page

Scroll to top